Yi Mufeng
About:
Yi Mufeng develops innovative and breakthrough tumor immune technology products to benefit the majority of patients with solid tumors.
Top Investors: SDIC Venture Capital, Guosheng Group
Description:
Total Funding Amount:
200M CNY
Headquarters Location:
Shanghai, Shanghai, China
Founded Date:
2020-07-16
Contact Email:
hr(AT)immunohead.com
Founders:
Number of Employees:
11-50
Last Funding Date:
2022-12-30
IPO Status:
Private
Industries:
© 2025 bioDAO.ai